PubMed Health⌕ Search

Biomedical subjects

P Boehm

Publications and source records attributed to P Boehm.

8 recordsLinked to original sources
PubMed1998

Chronic non-specific diarrhoea in childhood: how often is it iatrogenic?

Epidemiological data, the appropriateness of the medical approach, the effectiveness of unrestricted diet and the subsequent course of chronic non-specific diarrhoea (CNSD) were evaluated in 20 children, mean age at diagnosis 4.7 y, and mean duration of diarrhoea 24 months. A mean of 2.4 previous hospital admissions and a mean of 2.5 diagnoses other than CNSD were recorded per child before admission. On admission, 14/20 were following an elimination diet and 8/20 had an inadequate caloric intake; 16/20 had a weight/height ratio below the 50th percentile. In all cases a normal diet prescribed during hospitalization improved the diarrhoea and increased weight. A telephone interview performed 5.6 y after discharge revealed that in 10/20 of the cases, the parents were disappointed with the unrestricted diet prescribed during hospitalization. Nevertheless they reported that CNSD stopped spontaneously in a mean time of 1.7 y.

Adolescent↗
PubMed1997

Enhancement of hepatic parenchyma, aorta, and portal vein in helical CT: comparison of iodixanol and iopromide.

OBJECTIVE: The purpose of this study was to determine hepatic, aortic, and portal vein enhancement with a new dimeric, nonionic, isotonic contrast medium (iodixanol) in a routinely performed helical CT protocol and compare enhancement characteristics with those of a monomeric, nonionic, low-osmolality contrast medium (iopromide). SUBJECTS AND METHODS: In 81 patients, we injected 150 ml of iodixanol (320 mg I/ml), iodixanol (300 mg I/ml), or iopromide (300 mg I/ml). Injection rate was 5 ml/sec. A dual-phase helical CT scan was obtained (first helical scan began at 30 sec. second helical scan began at 70 sec), and enhancement characteristics were assessed. Results were analyzed taking into account various intrinsic parameters of patients. RESULTS: During the second imaging phase, iodixanol at 320 mg I/ml and iodixanol at 300 mg I/ml provided significantly higher enhancement of the liver (75 H, 69 H, 62 H), aorta (144 H, 140 H, 122 H), and portal vein (147 H, 147 H, 118 H) than did iopromide at 300 mg I/ml. No significant differences were observed during the first imaging phase. CONCLUSION: The combination of higher vascular and parenchymal enhancement levels after injection of the isotonic agent may represent a different quality of tissue enhancement. Such an enhancement would be characterized more by a higher contribution of the blood pool compartment to absolute enhancement levels than by a contribution of the interstitial compartment. Further studies are needed to determine whether the use of isotonic agents effects lesion conspicuity.

Aorta, Abdominal↗
PubMed1994

Aminohydroxypropylidene-biphosphonate in the treatment of bone lesions in a case of Gaucher's disease type 3.

Gaucher disease is the most prevalent lysosomal storage disorder. It is characterized by an autosomal recessive inheritance of a deficiency of lysosomal acid glucocerebrosidase. Three clinical phenotypes are recognized: type 1 (non-neuronopathic), type 2 (acute neuronopathic), type 3 (subacute neuronopathic). Bone lesions are associated with type 1 and type 3 Gaucher disease. Skeletal involvement is secondary to the progressive accumulation of histiocytes and macrophages laden with glucosylceramide in bone marrow. Our patient was a female type 3 Gaucher patient who was referred to us at the age of 3 years with a neurological symptomatology and severe bone lesions (bilateral fracture of the femur heads, lytic process of the bone matrix of the femurs and distal flask deformity, kyphoskoliosis and chest deformity). The baby was constrained to a wheel-chair. The use of (3-amino-1-hydroxypropylidene)-1,1-biphosphonate (APD) was described in a case of Gaucher disease with very severe bone lesions. We used periodic iv infusions of APD (10 mg every 3 weeks) in our patient for a period of 20 months; after that, enzyme replacement therapy (alglucerase) was commenced. APD treatment showed normalization of bone density, formation of bone callus at the femural heads, positive calcium balance. The urinary Ca/Cr ratio and TRP were consistently normal during therapy. After 9 months of alglucerase therapy the patient was able to walk again. The data indicate that APD therapy can find an indication in Gaucher patients with severe bone involvement.

Bone Diseases↗
PubMed1985

Inactivation of bacteria and viruses in water: passage of germicidal ultraviolet light through Teflon.

Teflon pipe as used in a water purification system transmitted germicidal ultraviolet (UV) light to inactivate Pseudomonas aeruginosa and poliovirus. The information is useful for animal care workers and others concerned with the prevention of microbial growth in water systems such as deionizers and distilled water. Of special significance is that there is a plastic that transmits UV light.

Poliovirus↗
PubMed1981

In vitro activity of 2-alkyl-3-hydroxy-1,4-naphthoquinones against Theileria parva.

A variety of naphthoquinones have veen prepared and evaluated in vitro against the causative agent of the cattle disease East Coast Fever-Theileria parva infection. It is concluded from structure-activity studies that a 2-hydroxyl moiety es essential for high activity. The most active compounds tested were 2-hydroxy-3-alkyl-1,4-naphthoquinones in which the alkyl moiety was cyclohexyl, cyclohexylcyclohexyl, tridecyl, or tetradecyl.

Animals↗
PubMed1980

[Studies on the activity of the aryl hydrocarbon hydroxylase and metabolism of benzo(a)pyrene in cell strains and cell lines used for testing cytotoxic and transforming ability of foreign compounds (author's transl)].

The activity of the AHH and the formation of polar metabolites from BaP was examined in several cell strains and lines, which are used for testing cytotoxic and transforming activity of environmental agents, the highest activity of the AHH and the highest capacity to metabolize BaP was found in hamster kidney cells. Much lower values were measured in kidney cells from Cercopithecus aethiops, BHK21/C13 cells, and SV-40 transformed hamster kidney cells (14-1b). The activity of AHH was inducible by BA in all these cells. However no correlation could be established between the increase in AHH activity and the formation of polar metabolites. In cells derived from a human bronchial carcinoma (E-14), a very low BaP metabolism was detectable which increased 3-fold after exposure (o BA. No BaP metabolism could be detected in HeLa cells.

Animals↗
PubMedDate not supplied

[Comparison of high-dose immunoglobulin and cyclosporine in newly diagnosed diabetic children].

A controlled trial was carried out on type I diabetic children to evaluate and to compare the clinical effects of two different kinds of immunotherapy: high doses intravenous gammaglobulin (IVIgG) and cyclosporine A (CyA). 30 newly diagnosed patients were admitted to the trial, 10 of whom served as controls (group A), 10 received 400 mg/kg b.w. of IVIgG on 5 consecutive alternate days and subsequently after 15 days and monthly thereafter for up to six months (group B), 10 patients received CyA 5-10/kg b.w. by mouth in two daily doses for a period comprised between 6 and 18 months (group C). Serum post-prandial C-peptide level was significantly higher after 6 months in group B and C than in group A; after 12 months, only group C showed significantly higher values. This difference was no longer significative at 18 and 24 months. Insulin requirement in the treated groups was significantly lower than in control group at 6 months, this difference was no longer significative at 12 months. We didn't find any difference concerning insulin requirement during the study comparing the two groups treated with the two different immunosuppressive therapies. In 3 patients in group B and in 3 patients in group C we didn't observe any appreciable response to immunosuppressive therapy (defined as insulin requirement greater than 0.5 UI/kg b.w. at 6 months and/or greater than 0.8 UI/kg b.w. at 12 months). We couldn't find any significant difference between responders and not responders to the immunosuppressive therapies regarding age, symptoms lasting before the diagnosis, weight loss, ketoacidosis intensity and serum post-prandial C-peptide level at the onset.(ABSTRACT TRUNCATED AT 250 WORDS)

Adolescent↗